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Abstract: The history of dialysis and diet can be viewed as a series of battles waged against potential
threats to patients’ lives. In the early years of dialysis, potassium was identified as “the killer”, and
the lists patients were given of forbidden foods included most plant-derived nourishment. As soon
as dialysis became more efficient and survival increased, hyperphosphatemia, was identified as
the enemy, generating an even longer list of banned aliments. Conversely, the “third era” finds
us combating protein-energy wasting. This review discusses four questions and four paradoxes,
regarding the diet-dialysis dyad: are the “magic numbers” of nutritional requirements (calories:
30–35 kcal/kg; proteins > 1.2 g/kg) still valid? Are the guidelines based on the metabolic needs of
patients on “conventional” thrice-weekly bicarbonate dialysis applicable to different dialysis schedules,
including daily dialysis or haemodiafiltration? The quantity of phosphate and potassium contained in
processed and preserved foods may be significantly different from those in untreated foods: what are
we eating? Is malnutrition one condition or a combination of conditions? The paradoxes: obesity is
associated with higher survival in dialysis, losing weight is associated with mortality, but high BMI is
a contraindication for kidney transplantation; it is difficult to limit phosphate intake when a patient is
on a high-protein diet, such as the ones usually prescribed on dialysis; low serum albumin is associated
with low dialysis efficiency and reduced survival, but on haemodiafiltration, high efficiency is coupled
with albumin losses; banning plant derived food may limit consumption of “vascular healthy” food in
a vulnerable population. Tailored approaches and agreed practices are needed so that we can identify
attainable goals and pursue them in our fragile haemodialysis populations.
Keywords: diet; dialysis; haemodialysis; protein energy wasting; serum albumin Kt/V; dialysis
efficiency; phosphate; survival
1. Diet and Dialysis: A Changing Picture
The history of dialysis and the nutritional approach in dialysis are closely connected; over time,
the definition of dietary needs and limitations has reflected the major advances in renal replacement
therapy and the changes that have taken place in the demography of the dialysis population.
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In this review we will attempt to contextualize some open question related to the diet and dialysis
dyad. We will start by describing the three “eras” of diet-in-dialysis, each marked by a battle against
a different threat to patients’ lives, and each associated with different problems, restrictions and
indications (Table 1).
Table 1. A simplified historical scheme of the main focuses in diets for patients on
chronic haemodialysis.
Period * The Main“Enemy” The Risks Dietary Indications Notes
First era Potassium Hyperkalemia canbe deadly
Restrictions on fruit
and vegetables
Can be mitigated by
high dialysis efficiency
and acidosis control
Second era Phosphate Vascular calcification,vascular ageing
Restrictions on cheese,
milk and derivates
May contrast with the
indications of
high-protein intake
Third era Malnutrition Risk of death is higher inmalnourished patients
Increased protein and
calorie intake
May be impossible to
conciliate with previous
restrictions
* The definition of each period is approximate, as each one merges with the next, and the first warnings on
malnutrition are as old as dialysis itself, while we should always keep in mind the short-term risks of hyperkalemia
and the long-term importance of hyperphosphatemia.
We will then discuss some questions still being debated and problems that have remained
unsolved, trying to indicate the practical implications of some of the open issues and paradoxes
(Table 2).
Table 2. A synthesis of the present panorama on diet and dialysis through four open questions and
four paradoxes.




proteins > 1.2 g/kg) still
relevant?
International standard
followed for more than
40 years
The requirements were assessed
in a different dialysis population,
and may not be relevant to the
present one; they do not consider
the changes in the indications
given to the overall population
There is a need for a re-assessment
of the requirements of elderly
dialysis patients
Are the present standards
of “adequate nutrition”
applicable to intensive
dialysis schedules, and to
haemodiafiltration?
Simple markers such as
albumin level make it
possible to compare results,
and are robust enough to
maintain a constant
predictive value
Sensibility may be lower in non
conventional dialysis techniques,
and can be affected by albumin
losses in haemodiafiltration
None of the proposed evaluations
of malnutrition is clearly superior
or self-standing; results of studies
depend in part on the
definition-diagnoses chosen
Processed and preserved
food may be significantly
different from untreated
food. What are we eating?
Nutritional approaches have
to be simple and basing
them on quantity and
quality may not be feasible




importance of additives in
processed and preserved foods
can lead to unnecessary
restrictions
Is malnutrition a single
disease or the result of
several diseases?
The clinical signs of
malnutrition are universal
and do not depend on
pathogenesis
If malnutrition is not linked to
poor intake but to poor clinical
conditions, itwill not respond
to therapy
Differentiation may allow setting




population or general data
in the dialysis population)
The finding (in the dialysis




Obesity is associated with
lower survival in the overall
population
Obesity is associated with higher
survival in dialysis patients;
losing weight is associated with
higher mortality on dialysis
Obesity is often a contraindication
for kidney transplantation
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Table 2. Cont.
The Questions Pros Cons Comments
High protein intake and
phosphate control
A high protein diet is
indicated after dialysis start
Reduction of phosphate intake is
not compatible with a
high-protein diet
Plant derived phosphate may be
less well absorbed; acidosis










efficiency is coupled with
significant albumin losses
Albumin losses are incompletely
quantified; nutrition is probably
more important than high




Since dialysis patients are at
risk for hyperkalemia,
potassium is often restricted
Banning plant derived food to
avoid hyperkalemia limits
consumption of “vascular healthy”
food in a high-risk population
Hyperkalemia is still a rare, but
possible cause of death
2. Dialysis and Diet: Different Enemies in Different Periods
2.1. The First Era: Potassium as the Killer
Hyperkalemia and salt and water overload can prove fatal to dialysis patients, and in the early
days of dialysis, acute pulmonary oedema, severe hyperkalaemia and the co-occurrence of the two
conditions were frequent, and often deadly [1–3]. Due to the limited efficiency of dialysis, some dietary
habits often had fatal consequences. Acidosis, only later recognized as a main cause of increases
in pre-dialysis potassium, often failed to be diagnosed [4,5]. Particularly until the mid-seventies,
when dialysis became more widely available, dialysis start often followed a period of low-protein diet,
generally one that was far more rigid and draconian (“diet or die”) than the ones now prescribed [6–12].
Growing awareness of the loss of advantage (and increase of side effects) of protein restriction after
dialysis start set the stage for recommending a high-protein diet immediately after dialysis start.
Due to the high potassium content of much animal-derived food, which was preferred for its
higher protein content, the patient’s intake of plant-derived food was reduced, often to the point of
imposing a ban on fruit and vegetables [3,13,14]. In the same period, patients were often advised to
follow low-sodium diets, to limit thirst and weight gain, and were given long lists of forbidden foods,
including most plant-derived food products [13,15–17]. This resulted in life-saving but monotonous
and complex diets [3,13].
Increased dialysis efficiency, together with an ageing dialysis population, with lower nutritional
intake, has required that the problem be seen from a new perspective, and death due to hyperkalaemia
has become less frequent; where hyperkalaemia remains as a problem, it is generally linked to
acidosis, gastrointestinal bleeding, uncontrolled diabetes, or iatrogenic effects [18–21]. The present
focus on dietary habits is more on avoidance of added potassium in processed foodsthan on limiting
consumption of plant-derived aliments, whose importance for cardiovascular health is increasingly
recognized [3,13,20–26].
2.2. The Second Era: Phosphate as the Silent Killer
Increased survival rates brought to light clinical problems evident only in the long term,
summarized as rapid vascular aging in dialysis patients [27–32]. These conditions were sometimes
called survivors’ diseases, to emphasize that they had emerged only when the problem of short-term
mortality had been at least partially overcome. Imbalances in the calcium-phosphate-PTH axis were
identified as the main cause of rapid vascular ageing, and a high calcium-phosphate product was, and
still is, associated with vascular calcification, and increased risk of death [33–39].
As a consequence, dialysis patients received a new, even longer list of foods they had to cut down
on, potentially leading to the paradox of (protein) malnutrition induced by focusing on avoidance
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of phosphate-rich food. Only recently has attention focused on added phosphorus, distinguishing
between processed and unprocessed foods [13,14,40–47].
Hyperphosphatemia is not only the result of a nutritional pathogenesis, as it can be the result
of several conditions in which dietary restrictions are of scarce benefit, while they are frustrating for
patients and may even worsen protein-energy wasting. Hyperphosphatemia may be due to:
- a low dialysis dose, which is associated with higher mortality; conversely, hyperphosphatemia is
usually corrected with long dialysis sessions, or daily dialysis [48,49];
- uncontrolled hyperparathyroidism is not responsive to dietary measures; furthermore, it is often
connected with long dialysis vintage, which is in turn associated with poor nutritional status and
poor outcomes [50–53];
- a low PTH level (usually post-parathyroidectomy), is often a sign of adynamic bone disease,
another condition associated with impaired nutritional status and poor outcomes [54–56];
Conversely, in thrice-weekly dialysis, low pre-dialysis phosphate levels are often a sign
of protein energy wasting, and are associated with poor survival, especially if combined with
hypoalbuminemia [57,58]. The implementation of new treatments has to some extent diverted attention
from diet, while a new player, malnutrition, has emerged on the scene.
2.3. The Third Era: Malnutrition as the Killer
The ageing of the dialysis population and the possibility of attaining long-term survival through
dialysis and transplantation, has focused attention on the central role of malnutrition both in the
incident population (elderly, high comorbidity), and as a characteristic of patients with a long treatment
vintage [53,55–57,59–63]. Among the biomarkers associated with survival (Kt/V, Ca-P-PTH, acidosis,
etc.), the strongest is serum albumin, where a low value represents the most robust metabolic risk
marker [64–73].
In keeping with the importance of nutrition in dialysis, total cholesterol, another robust marker of
nutrition, is the second-most reliable marker of survival, with a “U” shaped curve, as will be discussed in
the case of obesity, the paradigm of reverse epidemiology [74,75]. Malnutrition is not merely the result of
insufficient food intake, or of insufficient dialysis, but may reflect cardiovascular comorbidity, associated
with inflammation (MIA, malnutrition, inflammation and artherosclerosis syndrome) [59,60,76–78].
As further discussed, the stronger the association with cardiovascular disease and inflammation, the
harder it is to correct malnutrition: eating more may not be enough (Tables 2 and 3).
3. Diet and Dialysis: Four Questions and Four Paradoxes
3.1. First Question: Are the “Magic Numbers” Still Valid?
A series of reference numbers were progressively integrated into the indications and guidelines
for the nutritional management of dialysis patients [79–86]. Some of these may prove to be too
high and others too low. In their updated and extensive recent review of the revised nutritional
recommendations, Biurete and coworkers discuss the changing attitudes to renal diet (and to diet in
the overall population), and Kalantar-Zadeh wonders if there is anything left to eat for our patients [13].
Some of the “magic numbers” set targets that are probably too high and those which are probably too
low to be attained in present clinical practice [13,22]:
Targets that may be too high:
- Energy: 30–35 kcal/kg of dry body weight
- Proteins: at least 1.2 g/kg of dry body weight
- Phosphate: 800–1000 mg/day
Targets that may be too low, especially when diuresis is partly preserved:
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- Water: as little as possible
- Sodium: not univocal; older guidelines recommend less than 100 mEq/day (5.8 g of NaCl)
- Potassuim: 2 g/day
It is interesting to note, however, that many of these often-cited numbers are either opinion
based, or derived from old studies, often ones that involved a relatively small number of cases, whose
characteristics no longer correspond to the profile of the patients now seen in our dialysis wards.
3.2. Second Question: Type of Dialysis Technique: Does It Matter?
Most nutritional indications on extracorporeal dialysis are based on the metabolic needs of
“conventional” thrice-weekly bicarbonate-buffered haemodialysis [79–86]. However, there is increased
acknowledgement that if dialysis is more frequent and/or sessions are longer, metabolic balance and
nutritional status are more easily restored [87–91]. The option of increasing dialysis frequency should
therefore be considered as a valid strategy for improving nutritional status.
A growing body of evidence on an extreme, albeit rare condition, pregnancy in dialysis
patients, indirectly shows the importance of the duration and frequency of treatment in maintaining
physiological balance and optimal nutritional status [92,93].
The diet-dialysis dyad is therefore modulated by dialysis prescriptions:
- On conventional thrice-weekly dialysis, dietary restrictions follow the need to maintain good
metabolic balance (diet has to follow dialysis);
- On intensive dialysis schedules, higher efficiency and/or frequency may make an unrestricted
diet possible (dialysis liberalizes diet);
- A particular case regards haemodiafiltration, in which high efficiency may be associated with
significant protein loss, and the role of this loss in the context of dialysis-related malnutrition has
still to be elucidated [94–99].
Overall, the current indications for the management of nutritional status in haemodialysis regard
non-diabetic adults on thrice-weekly haemodialysis of “standard duration”. Elderly and diabetic
patients were not included in the studies which defined our reference numbers; however, the definition
of “old age” has varied over time, from being over 50 in the 1970s, to being over 80 (sometimes over 90)
now. The same indications do not necessarily apply to children, incremental dialysis, quotidian
or nightly dialysis (and all variations of frequency), haemodiafiltration or haemofiltration, while
controversy exists on peritoneal dialysis, which is beyond the scope of this review [100,101].
3.3. Third Question: Processed or Unprocessed Food: What Are We Actually Eating?
The current approaches to nutritional counseling in dialysis are based on the calculation of the
nutritional content of raw, unprocessed food. However, in the processed and preserved food products
now widely consumed, the quantity of phosphate and potassium, and of other preservatives, taste
enhancers and chemical colorants may be high, which means that a processed food product differs
considerably from the natural one. In particular in the case of phosphate, it is not only the quantity
that matters, but also the quality, as added inorganic phosphate is usually rapidly absorbable, and
therefore more dangerous [102–111].
In this regard, the warnings on red meat are linked to those on processed meat, and the question
is whether the risks are due to the additives and preservatives used or to the red meat itself [107–111].
The issue is even more complex if pesticides and trace elements are considered. For instance, fish
fed with animal proteins are extremely rich in phosphate, in contrast with wild fish. However, the
high content of heavy metals, mercury in particular, in large wild fish is also known, and another high
risk category, that of pregnant women, are counseled to avoid eating them, as mercury can impede
foetal growth. While our knowledge of such hidden dangers in the overall population is constantly
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accumulating, the little that is known about dialysis patients identifies them as a population at high
risk for the chronic poisoning agents of our polluted world [112–116].
3.4. Fourth Question: How Should Malnutrition Be Seen?
When protein energy wasting was identified as one of the major causes of death in dialysis, the
“under-dialysis syndrome” was often seen as the basis of this deadly condition [59,60,76–78,117,118].
The first studies on daily and nightly dialysis supported this interpretation [119–126]. The hypothesis
advanced was therefore that eating better and more was possible and should be accompanied by better
dialysis, and with attention to control of metabolic acidosis [117,118,127–130].
The aging of the dialysis population revealed the importance of new players: diffuse vascular
disease and chronic inflammation merged with malnutrition in the malnutrition, inflammation and
atherosclerosis (MIA) syndrome [59,60,76–78,131–135].
Hence, two different forms of malnutrition were identified:
- Protein energy wasting due to “poor nutrition”, related to low nutrient intake, in turn
linked to incomplete correction of metabolic balance, insufficient dialysis, non biocompatible
membranes, poorly controlled hypertension, combined with an overly restricted diet. This
form of malnutrition generally responds to nutritional intervention, after optimization of the
dialysis schedule.
- Protein energy wasting as a result of poor clinical conditions: the prototype is the MIA syndrome,
mentioned above. This type of malnutrition is less responsive to nutritional interventions and its
prognosis is linked to the patient’s life expectancy (Figure 1).
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4. Diet and Dialysis: Four Paradoxes
4.1. First Paradox: Energy Intake and Obesity
In the overall population obesity is associated with higher morbidity and mortality; hence the
longer survival of obese patients in dialysis, the paradigm of reverse epidemiology, was initially
surprising [136]. The effect of weight on survival on dialysis produces a u-shaped curve: in the
short term, the highest risk is for underweight, malnourished patients, but obese patients, who are
initially not affected by malnutrition, may pay a price in terms of mortality and comorbidity in the
long run [137]. The association is observed in all dialysis populations, in chronic kidney disease and is
modulated by dialysis efficiency, diabetes and sex [136–140] (Figure 2).
While life expectancy is longer after kidney transplantation, high BMI is an important
contraindication for transplantation (although not an automatic disqualification in all centers), due
to the poorer results obtained in obese patients [141–148]. Thus the paradoxical exclusion of obese
patients, who are likely to have a longer life expectancy, from many transplant programs, underlines
the many controversial facets of nutrition in dialysis [147].
The balance between the advantages and disadvantages of obesity varies across CKD phases
(Figure 2). Obesity increases the risk of progression of CKD, and weight loss is advised in
pre-dialysis patients. Obesity displays a survival advantage in dialysis, but represents a barrier
for kidney transplantation; the indications to lose weight on dialysis are controversial, leading some
authors to suggest that weight loss programs be limited to patients potentially waitlisted for kidney
transplantation [138]. It is not easy for dialysis patients to lose weight and the associated benefit
is not clear-cut, and may be absent [149–152]. As the risks of bariatric surgery are increasingly
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The conflicting pattern of obesity-related risks across CKD phases suggests that obesity is not
healthy per se, but it protects the patient from the dangers of malnutrition on dialysis in the same way
as it protected our ancestors from dying in times of famine in prehistoric times [153]. In this sense,
dialysis may be another example of the advantage of “thrifty” genotypes (Figure 2).
The differences between patterns of overweight/obesity suggest a tailored approach to obese
dialysis patients, optimally within a flexible policy of transplant waitlisting [154,155]. Intensifying
dialysis, thereby allowing for safer weight loss, is a support policy that should be considered [156].
4.2. Second Paradox: Phosphate, Acidosis and Protein Intake
The traditional approach involves starting a high-protein diet (1.2–1.4 g/kg/day of protein)
immediately before renal replacement therapy, to compensate for strict pre-dialysis diets. In fact
protein loss via haemodialysis, is a problem that has been known since the early years of renal
replacement therapy [37–40,96–99,157].
This recommendation should be contextualized to the state of our knowledge in the late 70s and
early 80s, in a younger dialysis population with late-start dialysis, lower efficiency, pre-erythropoietin,
before the catabolic effect of acidosis was fully acknowledged. This may not fully apply to our ageing
dialysis population [158,159].
Unfortunately high protein intake is not without side effects: fixed acid production increases
on a protein rich diet (in particular one with a preponderance of food of animal origin), as does
phosphate load, thus leading to a conflict between ensuring high protein intake or correcting acidosis
and hyperphosphatemia [40–47].
Three points need to be underlined in this regard:
- Conflict between protein and phosphate is limited to thrice-weekly dialysis, while more frequent
sessions, in particular nightly haemodialysis schedules, can remove so much phosphate that it
becomes necessary to add phosphate to the dialysate [48,49,90,91,119–123].
- Not all phosphate is created equal: plant organic phosphate is less absorbable than phosphate in
animal protein. Added inorganic phosphate, found in food preservatives, is devoid of nutritional
benefit and is more easily absorbed; information on added phosphate is however often lacking
from packaging [102–106].
- The role of animal-derived proteins in human nutrition has been reassessed in recent years,
yet this critical analysis has not been fully extended to CKD and dialysis patients, for whom
the equation “high quality protein = animal-derived protein = best protein” is still the basis for
prescription, even if the interest on plant-based diets in all CKD stages is increasing [106–111,160–162].
Current approaches are more flexible regarding phosphate restriction, and are mainly aimed
at avoiding added phosphate, increasingly recognized as unhealthy in CKD patients as well
as in the overall population. A more liberal intake of plant-derived phosphate, together with
attention to avoiding food additives, is probably compatible with good metabolic control and less
need for phosphate binders, which account for a relevant portion of the pill burden in dialysis
patients [160–167]. The awareness that hyperphoshatemia reflects a variety of nutritional and
non-nutritional derangements can guide tailored interventions [167] (Figure 3).
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4.3. Third Paradox: High-Efficiency Dialysis and Serum Albumin Levels
For over three decades, insufficient dialysis has been associated with poor outcomes and protein
energy wasting [65–70,168,169].
High-flux dialysis/haemodiafiltration, with biocompatible membranes and ultrapure water
have a higher efficiency profile and are generally better tolerated, as is peritoneal dialysis [170–178].
However, one of the prices to pay is the increased loss of amino acids and of small size proteins, that
can account for several grams of albumin loss per session [179–181].
This accounts for another paradoxical situation: the most biocompatible membranes, including
the peritoneal one, and the highest ultrafiltration efficiency on extracorporeal dialysis are associated
with lower serum albumin lev ls, hence with a robust m rker of poor survival (Figure 4) [179–181].
Albumin losses have been quantified differently, and the heterogeneity depends on several factors:
- On extracorporeal dialysis, albumin loss depends on the type of dialysis membranes used,
dialysis, hematocrit, albumin and total protein level, blood and dialysate flows; due in part to the
difficulty of sampling, few studies have assessed the intersession variability of albumin losses in
individual patients, in stable conditions and in specific situations, such as inflammatory states;
- No validated standardized method is available in clinical practice for dosing albumin levels at
the low concentrations usually attained in the dialysate;
As will be further discussed, a missing piece of the puzzle is albumin synthesis, which is reduced
in patients with chronic inflammation or severe vascular disease, once more linking nutrition and
dialysis efficiency with inflammation and atherosclerosis; as some authors claim that prealbumin may
be a better nutritional marker in these cases, the controversy is still open [182–184].
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4.4. Fourth Paradox: Potassium and Vascular Health
Seeking healthy nutrition has become fashionable: in most European countries, television and
advertisements remind the public that healthy nutrition includes at least two servings of fruit and
vegetables per day. The attention paid to the Mediterranean Diet, DASH and vegan-vegetarian diets
underlines the importance of an adequate potassium intake for the prevention of cardiovascular
diseases and highlights the risks linked to diets overly rich in animal proteins [185–192]. Similar data
are observe in CKD patie ts, in which a “h althy” diet is associated wit long survival [193–195].
Yet it s d fficult to reconcile the first killer of dialysis p tients with the emerging nutritional indications.
Although patients on dialysis ar generally nstructed to avoid fruit and vegetables, otassium
is ubiquitous, and rotein-rich food is often also rich in potassium. In fact, s was pointed out,
limitations on potassium-rich food are not fully supported by the current literature, and a more liberal
consumption of plant-derived food is probably to be advised, also because it reduces constipation
(Figure 5) [14,22,167]. Once more, attention should be paid to the potassium contained in food
preservatives rather than in fresh fruit and vegetables, while careful management of acidosis and
tailored dialysis schedules can offer alternatives to dietary restrictions [14,22–26].
The use of potassium binders, potentially useful in liberalizing the “renal diet”, is still matter
of discussion, both with the older polystyrene resins, whose use combined with laxatives has
been associated with intestinal ischemia, and with the new potassium binders, Patiromer, and
Zirconium Cyclosilicate (ZS-9), the first however associated with electrolyte depletion (in particular
hypomagnesemia) and the second with an increased risk of edema [196–199].
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5. What This Review Did Not Address
This review was undertaken to support the dietitian and nursing team in our hospital
(Centre Hospitalier Le Mans, France) by providing a summary of the open problems and ongoing
discussions in the clinical management of diet in haemodialysis patients. It does not focused on the
main strategies for correcting malnutrition, briefly summarized in Table 3. It did not address many
important points, including the diagnosis of malnutrition or protein energy wasting; the organization
of the dietitian’s support to the dialysis population; the psychological aspects of malnutrition and its
relationship with depression; the role of uremic toxins; the reversibility of malnutrition after kidney
transplantation and the role of macrobiotics. The acknowledgement of these limitations underlines the
complexity of the issue and the need for continuous updating in this complex and evolving field.
Table 3. A schematic revision of limits and advantages of interventions to improve the nutritional
status of dialysis patients.
The Field of
Intervention Intervention Pros Cons
Dialysis
optimization
Increasing effici nc and tolerance by
increasing frequency (daily or more
frequent dialysis) [200–213]
Improvement in nutritional status in
most of prospective studies (see also
pregnancy on dialysis)
May be difficult to organize;
possibly higher risk of vascular
c ess problems
Increasing efficiency and probably
also tolerance by switching to
convective dialysis modalities
(such as high flow
haemodiafiltration) [214–226]
Efficiency is associated with
nutritional status at least in
“standard patients”
Losses may be significant in
elderly, malnourished patients.
No demonstration of nutritional
advantages
Decreasin losses, and preserving
renal function (incremental dialysis,
tailored dialysis) [227–242]
Residual diuresis and residual renal
function are two of the most powerful
predictors of survival; “dialysis shock”
may be a cause of early death after
dialysis start
Experience is still limited and
there is still no agreed standard
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Table 3. Cont.
The Field of
Intervention Intervention Pros Cons
Physical
exercise
Physical exercise is theoretically a
powerful means of improving clinical
conditions and nutritional status in
patients with a chronic
disease [243–252]
The best results have been reported in
observational studies; biases linked to
self-selection limit the generalization
of results.
Barriers are evident in the
elderly population, in which







ESA improved quality of life, fertility
and sex life, issues associated with
nutritional status
The association between lack of
response to ESAs, inflammation,
malnutrition and atherosclerosis
is part of the MIA syndrome
Thyroid hormones [255]
The euthyroid sick syndrome or “low
T3 syndrome” is typical of
malnutrition/starvation
Correction of the metabolic




options include nandrolone decanoate
and oxymetholone, which display
good effects on sarcopenia
Side effects may be relevant; this
treatment could be considered




Recombinant growth hormone is
routinely used in children on dialysis.
In adults, growth hormone is often
low, and the effect on severe
malnutrition has been favorable




Increasing the quantity/quality of
food [268–278]
The best tool for improving
nutritional status, eating during
dialysis may be an important way to
improve the nutritional status of
dialysis patients
If malnutrition is linked to
inflammation and
atherosclerosis, it is difficult to




Can be of use especially for limited
periods of time; specific supplements
for dialysis patients (poor in
phosphate) are also available
Can decrease appetite for
“normal” food; may be less tasty
after a longer period
Intravenous or enteral
supplements [293–295]
Can help reverse acute malnutrition,
especially in the case of failure of the
two previous interventions
May further reduce food intake;
and create a need for a high
quantity of fluids; metabolic
derangements are frequent in
the long term
* All major metabolic derangements, including acidosis, hyperparathyroidism and hypovitaminosis D, are associated
with poor nutritional status and higher mortality in dialysis.
6. Conclusions and Suggestions for Future Research
Dialysis and diet are a dyad that cannot be divided if we wish to ensure the best possible
metabolic balance in our patients. In taking into account the improvements in dialysis treatment and
the demographic changes in the dialysis population, current dietary approaches are less restrictive
than those adopted in the past, and flexible and tailor-made diet-dialysis policies are gaining interest.
The vast literature on ways that malnutrition can be prevented or reversed has often produced
inconsistent results, indirectly supporting personalized interventions, and demonstrating the need
for dedicated, committed and specialized multidisciplinary teams of professionals with nutritional,
educational and rehabilitation skills in the core clinical management of dialysis patients.
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